Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity.

Literature DB >> 12446014

TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity.

Sophie Desplat-Jégo¹, Simone Varriale, Rita Creidy, Rafik Terra, Dominique Bernard, Michel Khrestchatisky, Shozo Izui, Yves Chicheportiche, José Boucraut.

Abstract

TWEAK is a new TNF family member with proinflammatory and proliferative effects on different cell types, mediated by the recently identified Fn14 receptor. TWEAK expression was analyzed on mouse microglial cells and astrocytes. Both cell types express TWEAK mRNA. Astrocytes expressed Fn14 and proliferated in the presence of rTWEAK. TWEAK mRNA is expressed in normal CNS and its steady state level increases in spinal cord during EAE. Finally, EAE severity is enhanced in soluble TWEAK-overexpressing transgenic mice. These results support the contention that TWEAK is involved in CNS inflammation.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2002 PMID： 12446014 DOI： 10.1016/s0165-5728(02)00368-5

Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478

Keyword Cloud
Cited

54 in total

1. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

Authors: Blythe C Dillingham; Susan M Knoblach; Gina M Many; Brennan T Harmon; Amanda M Mullen; Christopher R Heier; Luca Bello; John M McCall; Eric P Hoffman; Edward M Connor; Kanneboyina Nagaraju; Erica K M Reeves; Jesse M Damsker
Journal: Cell Mol Neurobiol Date: 2014-11-13 Impact factor: 5.046

2. Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth.

Authors: Katsuhisa Tanabe; Iris Bonilla; Jeffrey A Winkles; Stephen M Strittmatter
Journal: J Neurosci Date: 2003-10-22 Impact factor: 6.167

Review 3. Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors: Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal: J Autoimmun Date: 2012-06-22 Impact factor: 7.094

4. Intracerebroventricular administration of TNF-like weak inducer of apoptosis induces depression-like behavior and cognitive dysfunction in non-autoimmune mice.

Authors: Jing Wen; Christopher Holden Chen; Ariel Stock; Jessica Doerner; Maria Gulinello; Chaim Putterman
Journal: Brain Behav Immun Date: 2015-12-23 Impact factor: 7.217

5. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors: R Pattarini; R J Smeyne; J I Morgan
Journal: Neuroscience Date: 2007-01-29 Impact factor: 3.590

10. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Authors: Steffen Salzmann; Axel Seher; Johannes Trebing; Daniela Weisenberger; Alevtina Rosenthal; Daniela Siegmund; Harald Wajant
Journal: J Biol Chem Date: 2013-03-26 Impact factor: 5.157

TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity.

1. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

2. Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth.

Review 3. Role of TWEAK in lupus nephritis: a bench-to-bedside review.

4. Intracerebroventricular administration of TNF-like weak inducer of apoptosis induces depression-like behavior and cognitive dysfunction in non-autoimmune mice.

5. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

6. Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

Review 7. The TWEAK-Fn14 system as a potential drug target.

Review 8. TWEAK as a target for therapy in systemic lupus erythematosus.

Review 9. Advances in anticancer immunotoxin therapy.

10. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.